Krystal Biotech, Inc. Investigation - KRYS

Company
Krystal Biotech, Inc. (NASDAQ: KRYS)

Learn more about the Krystal Biotech, Inc. Investigation

Required Field

Required Field

Required Field

  • $1 - $1,000
  • $1001 - $10,000
  • $10,001 - $25,000
  • $25,001 - $50,000
  • $50,001 - $100,000
  • $100,001 - $250,000
  • $250,001 - $500,000
  • $500,000+

There is no cost or obligation for you to submit.

The submission of this form does not create an attorney-client relationship.

Please Upload related files below

Add Transactions

Purchases

1.
  • Common Stock
  • Preferred Stock
  • Bonds
  • Calls
  • Puts
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12

Additional Purchases

Sales

1.
  • Common Stock
  • Preferred Stock
  • Bonds
  • Calls
  • Puts
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12

Additional Sales

Please input at least 1 transaction or press "skip for now" button below

Please fill in all the fields for your transaction or press "skip for now" button below

Alternatively, you may upload your transactions below or e-mail them to [email protected]

Upload Your Stock Tickers

Tell us the stocks you own using SnapTrade, and we will keep you informed about class action litigation related to your stocks. We monitor critical case developments that may affect the price of your shares and your possible monetary recovery. SnapTrade only shares the tickers you own and your transaction history, not your account numbers. Using SnapTrade and participating in our monitoring service is free and does not create any attorney-client relationship or obligation on your part.

Don’t miss out on possible monetary recovery - link your brokerage account with SnapTrade.

Krystal Biotech, Inc. Investigation Details

Krystal Biotech, Inc. shares fell $36.39 per share, or 10.95%, on November 2, 2026, closing at $295.90, after the Company announced its operating and financial results for the third quarter ended September 30, 2026. In that announcement, the Company disclosed that data releases for several of its product candidates would not be released until 2027. Earlier, the Company had stated that such data would be available by the end of 2026, making the November 2, 2026 announcement a change from the timeline investors had been given. The decline followed that same-day disclosure, and the move in the share price reflects how the market responded to the revised timing for the product candidate data. The investigation concerns whether Krystal Biotech, Inc. and certain of its officers and directors adequately disclosed the status and expected timing of data releases for these product candidates, and whether statements about data being available by the end of 2026 reflected the information available to the Company at the time those statements were made. The investigation concerns whether Krystal Biotech adequately disclosed that data releases for several of its product candidates would be delayed into 2027 ahead of the November 2, 2026 announcement.

Get Started